Latest Insider Transactions at Apimeds Pharmaceuticals Us, Inc. (APUS)
This section provides a real-time view of insider transactions for Apimeds Pharmaceuticals Us, Inc. (APUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apimeds Pharmaceuticals US, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apimeds Pharmaceuticals US, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2025
|
Christopher Kim Chairman and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+47.39%
|
-
|
|
May 16
2025
|
Erik C. Emerson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
750,000
+50.0%
|
-
|
|
May 14
2025
|
Christopher Kim Chairman and CMO |
BUY
Open market or private purchase
|
Direct |
7,730
+21.94%
|
$7,730
$1.86 P/Share
|
|
May 13
2025
|
Christopher Kim Chairman and CMO |
BUY
Open market or private purchase
|
Direct |
19,770
+50.0%
|
$19,770
$1.82 P/Share
|
|
May 12
2025
|
Jakap Koo Director |
BUY
Open market or private purchase
|
Direct |
28,500
+4.24%
|
$28,500
$1.99 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
44,041
+2.12%
|
$88,082
$2.6 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
253,092
+2.82%
|
$506,184
$2.6 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
500,000
+20.12%
|
$2,000,000
$4.0 P/Share
|